AstraZeneca PLC (NASDAQ:AZN – Free Report) – Zacks Research raised their Q1 2025 EPS estimates for shares of AstraZeneca in a note issued to investors on Monday, December 30th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $1.07 for the quarter, up from their previous forecast of $1.06. The consensus estimate for AstraZeneca’s current full-year earnings is $4.11 per share.
AstraZeneca (NASDAQ:AZN – Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. The company had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. AstraZeneca’s revenue was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.87 earnings per share.
View Our Latest Analysis on AZN
AstraZeneca Stock Up 0.5 %
Shares of AZN opened at $65.88 on Wednesday. The stock’s 50-day moving average price is $67.15 and its two-hundred day moving average price is $75.50. AstraZeneca has a 12 month low of $60.47 and a 12 month high of $87.68. The company has a market capitalization of $204.27 billion, a PE ratio of 31.52, a PEG ratio of 1.19 and a beta of 0.45. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of AZN. McClarren Financial Advisors Inc. grew its stake in AstraZeneca by 320.8% in the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after buying an additional 247 shares in the last quarter. GHP Investment Advisors Inc. purchased a new position in AstraZeneca in the second quarter worth $26,000. Capital Performance Advisors LLP bought a new position in AstraZeneca in the third quarter valued at $28,000. Groupama Asset Managment raised its position in AstraZeneca by 22.9% during the third quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock valued at $42,000 after purchasing an additional 101,225 shares in the last quarter. Finally, Ashton Thomas Securities LLC bought a new stake in AstraZeneca during the third quarter worth about $45,000. 20.35% of the stock is currently owned by hedge funds and other institutional investors.
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Recommended Stories
- Five stocks we like better than AstraZeneca
- Financial Services Stocks Investing
- 3 Legacy Tech Companies Reemerging as AI LeadersÂ
- Upcoming IPO Stock Lockup Period, Explained
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- How to Calculate Return on Investment (ROI)
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.